Ikram Abdikarim1, Xue-Yuan Cao1, Shou-Zhen Li1, Yin-Quan Zhao1, Yerlan Taupyk1, Quan Wang1. 1. Ikram Abdikarim, Xue-Yuan Cao, Shou-Zhen Li, Yin-Quan Zhao, Yerlan Taupyk, Quan Wang, Department of Gastric and Colorectal Surgery, First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Abstract
AIM: To study the efficacy of the enhanced recovery after surgery (ERAS) program in laparoscopic radical gastrectomy for stomach carcinomas. METHODS:From June 2010 to December 2012, 61 gastric cancer patients who underwentlaparoscopic-assisted radical gastrectomy with D2 lymphadenectomyat First Hospital of Jilin University were enrolled in this randomized controlled trial. (Clinical Trials.gov, registration ID: NCT01955096). The subjects were divided into the ERAS program group and the conventional control group. The clinical characteristics, recovery variables, and complications of patients were analyzed. RESULTS: The time to first ambulation, oral food intake, and time to defecation were significantly shorter in the ERAS group (n = 30), compared to the conventional group (n = 31; P = 0.04, 0.003, and 0.01, respectively). The postoperative hospital stay was less in the ERAS group (6.8 ± 1.1 d) compared to the conventional group (7.7 ± 1.1 d) (P = 0.002). There was no significant difference in postoperative complications between the ERAS (1/30) and conventional care groups (2/31) (P = 1.00). There were no readmissions or mortality during the 30-d follow-up period. CONCLUSION: The ERAS program is associated with a shorter hospital stay in gastric cancer patients undergoing laparoscopic radical gastrectomy. The ERAS protocol is useful in the treatment of gastric cancer.
RCT Entities:
AIM: To study the efficacy of the enhanced recovery after surgery (ERAS) program in laparoscopic radical gastrectomy for stomach carcinomas. METHODS: From June 2010 to December 2012, 61 gastric cancerpatients who underwent laparoscopic-assisted radical gastrectomy with D2 lymphadenectomy at First Hospital of Jilin University were enrolled in this randomized controlled trial. (Clinical Trials.gov, registration ID: NCT01955096). The subjects were divided into the ERAS program group and the conventional control group. The clinical characteristics, recovery variables, and complications of patients were analyzed. RESULTS: The time to first ambulation, oral food intake, and time to defecation were significantly shorter in the ERAS group (n = 30), compared to the conventional group (n = 31; P = 0.04, 0.003, and 0.01, respectively). The postoperative hospital stay was less in the ERAS group (6.8 ± 1.1 d) compared to the conventional group (7.7 ± 1.1 d) (P = 0.002). There was no significant difference in postoperative complications between the ERAS (1/30) and conventional care groups (2/31) (P = 1.00). There were no readmissions or mortality during the 30-d follow-up period. CONCLUSION: The ERAS program is associated with a shorter hospital stay in gastric cancerpatients undergoing laparoscopic radical gastrectomy. The ERAS protocol is useful in the treatment of gastric cancer.
Entities:
Keywords:
Enhanced recovery after surgery; Gastrectomy; Gastric cancer; Laparoscopic
Authors: U O Gustafsson; M J Scott; W Schwenk; N Demartines; D Roulin; N Francis; C E McNaught; J Macfie; A S Liberman; M Soop; A Hill; R H Kennedy; D N Lobo; K Fearon; O Ljungqvist Journal: World J Surg Date: 2013-02 Impact factor: 3.352
Authors: Young-Woo Kim; Yong Hae Baik; Young Ho Yun; Byung Ho Nam; Dae Hyun Kim; Il Ju Choi; Jae-Moon Bae Journal: Ann Surg Date: 2008-11 Impact factor: 12.969
Authors: Andreas Andreou; Sebastian Knitter; Sascha Chopra; Christian Denecke; Moritz Schmelzle; Benjamin Struecker; Ann-Christin Heilmann; Johanna Spenke; Tobias Hofmann; Peter C Thuss-Patience; Marcus Bahra; Johann Pratschke; Matthias Biebl Journal: J Gastrointest Surg Date: 2018-10-03 Impact factor: 3.452
Authors: Alisa N Blumenthaler; Kristen A Robinson; Brittany C Kruse; Kathryn Munder; Naruhiko Ikoma; Paul F Mansfield; Vijaya Gottumukkala; Ravish Kapoor; Brian D Badgwell Journal: J Surg Oncol Date: 2021-07-06 Impact factor: 2.885